Mirtazapine is a tetracyclic antidepressant marketed primarily for the treatment of major depressive disorder. Mirtazapine blocks central presynaptic alpha-2 adrenergic receptors as well as serotonin 5-ht2 and 5-ht3 receptors, which increases the release and activity of norepinephrine and serotonin. This synergistic blockade enhances mood-regulating neurochemical pathways and reduces anxiety-related signaling. By elevating norepinephrine and serotonin levels, Mirtazapine improves depressive symptoms such as low mood, loss of interest, and sleep disturbances. The medication also produces sedation through antagonism of histamine h1 receptors, which can be beneficial for patients with insomnia associated with depression. The combined effect of increased monoamine availability and reduced inhibitory tone helps restore normal mood regulation. Clinically, Mirtazapine is classified as a noradrenergic and specific serotonergic antidepressant, reflecting its unique pharmacological profile. Its ability to modulate these physiological processes underscores its role in treating major depressive episodes without requiring daily stimulant effects.

Mirtazapine is a prescription medication classified as a tetracyclic antidepressant used to treat major depressive disorder. It works primarily by blocking central presynaptic alpha-2 adrenergic receptors which increases the release of norepinephrine and serotonin. By also antagonizing histamine h1 receptors it produces sedative effects that can improve sleep in depressed patients. The drug's antagonism of serotonin 5-ht2 and 5-ht3 receptors contributes to its antidepressant efficacy with fewer gastrointestinal side effects. Mirtazapine does not significantly inhibit the serotonin transporter, distinguishing it from selective serotonin reuptake inhibitors. Its pharmacodynamic profile includes potent antagonism of several serotonin receptor subtypes which modulates mood regulation pathways. The net result is enhanced noradrenergic and serotonergic neurotransmission leading to improved mood and reduced depressive symptoms. This mechanism provides a therapeutic benefit without the need for direct reuptake inhibition or stimulation of dopamine pathways.

Mirtazapine may cause drowsiness or increased sleepiness in some individuals. It can also lead to weight gain due to increased appetite. Some people experience dry mouth as a common side effect. Dizziness or lightheadedness may occur, especially when standing up quickly. Occasionally, the medication can cause constipation or mild gastrointestinal discomfort. In rare cases, it may result in changes in heart rhythm or blood pressure. These effects are generally mild.

Mirtazapine can cause drowsiness, increased appetite, and weight gain. Some users may experience dizziness or dry mouth. It may also lead to constipation or mild nausea. Occasionally it can result in blurred vision or ringing in the ears. Rarely it is associated with changes in blood pressure or cholesterol levels. Some people notice a feeling of restlessness or agitation. It can occasionally cause sexual dysfunction or a reduced libido. Withdrawal symptoms such as irritability or insomnia may appear if the dose is stopped abruptly.